Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
How to buy Sutro Biopharma stock
Learn how to easily invest in Sutro Biopharma stock.
Sutro Biopharma is a biotechnology business based in the US. Sutro Biopharma shares (STRO) are listed on the NASDAQ and all prices are listed in US Dollars. Sutro Biopharma employs 259 staff and has a trailing 12-month revenue of around $69.8 million.
How to buy Sutro Biopharma stock
- Choose a stock trading platform. Use our comparison table or choose from our Top Picks below.
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds unto your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – STRO. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
- Trade stocks for $0 and no annual fee
- Start trading with a $0 minimum deposit
- Get up to $1,000 when you fund a new account within 30 days
- Easy to use platform with low fees
- Social trading allows you to copy popular portfolios
- FINDER EXCLUSIVE: Get $15 when you sign up and deposit $100
- Get free stock upon signup
- Earn 4% interest on uninvested cash with Robinhood Gold
- Get 1% match on contributions to a Robinhood IRA
Sutro Biopharma stock price (NASDAQ: STRO)Use our graph to track the performance of STRO stocks over time.
Sutro Biopharma shares at a glance
|Latest market close||$6.87|
|52-week range||$3.33 - $10.15|
|50-day moving average||$7.52|
|200-day moving average||$6.21|
|Wall St. target price||$22.13|
|Dividend yield||$0 (0%)|
|Earnings per share (TTM)||$-2.47|
Buy Sutro Biopharma stocks from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
Is it a good time to buy Sutro Biopharma stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Sutro Biopharma price performance over time
|1 week (2023-01-31)||-5.11%|
|1 month (2023-01-06)||-16.32%|
|3 months (2022-11-07)||-8.76%|
|6 months (2022-08-05)||19.27%|
|1 year (2022-02-03)||-28.88%|
|2 years (2021-02-05)||-73.94%|
|3 years (2020-02-07)||11.75|
|5 years (2018-02-03)||N/A|
Sutro Biopharma financials
|Revenue TTM||$69.8 million|
|Gross profit TTM||$-42,520,000|
|Return on assets TTM||-18.56%|
|Return on equity TTM||-47.82%|
|Market capitalisation||$421.3 million|
TTM: trailing 12 months
Sutro Biopharma share dividends
We're not expecting Sutro Biopharma to pay a dividend over the next 12 months.
Sutro Biopharma share price volatility
Over the last 12 months, Sutro Biopharma's shares have ranged in value from as little as $3.33 up to $10.15. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Sutro Biopharma's is 0.9323. This would suggest that Sutro Biopharma's shares are less volatile than average (for this exchange).
Sutro Biopharma overview
Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+. The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers, which is in Phase 1 clinical trials. It has collaboration and license agreements with Merck Collaboration to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; and Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc.
Sutro Biopharma in the news
Are Investors Undervaluing Sutro Biopharma, Inc. (NASDAQ:STRO) By 46%?
Sutro Biopharma Posts Updated Data From Ovarian Cancer Candidate
Sutro Biopharma Announces Update from STRO-002, Luveltamab Tazevibulin (Luvelta), Phase 1 Dose-Expansion Study and Registrational Plans in Advanced Ovarian Cancer
Frequently asked questionsWhat percentage of Sutro Biopharma is owned by insiders or institutions?
Currently 5.654% of Sutro Biopharma shares are held by insiders and 89.525% by institutions. How many people work for Sutro Biopharma?
Latest data suggests 259 work at Sutro Biopharma. When does the fiscal year end for Sutro Biopharma?
Sutro Biopharma's fiscal year ends in December. Where is Sutro Biopharma based?
Sutro Biopharma's address is: 111 Oyster Point Boulevard, South San Francisco, CA, United States, 94080 What is Sutro Biopharma's ISIN number?
Sutro Biopharma's international securities identification number is: US8693671021 What is Sutro Biopharma's CUSIP number?
Sutro Biopharma's Committee on Uniform Securities Identification Procedures number is: 869367102
More guides on Finder
How to buy Neuraxis (NRXS) stock when it goes public
Everything we know about the Neuraxis IPO, plus information on how to buy in.
How to buy TXO Energy (TXO) stock
Everything we know about the TXO Energy IPO, plus information on how to buy in.
How to buy Brera (BREA) stock
Everything we know about the Brera IPO, plus information on how to buy in.
How to invest in the S&P 500
What you need to know about investing in the leading indicator for the overall US stock market.
How to buy IPO stock
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
How to buy Novo Integrated Sciences stock
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
How do ETFs work?
Your simple and straightforward guide to ETFs, how they work and the different types available.
What is stock lending?
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.
How to buy SONDORS (SODR) stock when it goes public
Everything we know about the SONDORS IPO, plus information on how to buy in.
How to buy Bullfrog AI Holdings (BFRG) stock when it goes public
Everything we know about the Bullfrog AI Holdings IPO, plus information on how to buy in.
Ask an Expert